Ixabepilone and Liposomal Doxorubicin in Advanced Ovarian Cancer



Status:Completed
Conditions:Breast Cancer, Ovarian Cancer, Cancer, Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:18 - Any
Updated:4/21/2016
Start Date:January 2006
End Date:May 2014

Use our guide to learn which trials are right for you!

A Phase I/II Study of BMS-247550 and Pegylated Liposomal Doxorubicin (Doxil®) in Patients With Advanced Epithelial Ovarian Cancer or Primary Peritoneal Cancer Who Have Been Previously Treated With a Platinum and a Taxane

This trial is studying the side effects and best dose of ixabepilone when given together
with pegylated liposomal doxorubicin hydrochloride and to see how well they work in treating
women with advanced ovarian epithelial, primary peritoneal cavity, or fallopian tube cancer
or metastatic breast cancer. Drugs used in chemotherapy, such as ixabepilone and pegylated
liposomal doxorubicin hydrochloride, work in different ways to stop the growth of tumor
cells, either by killing the cells or by stopping them from dividing. Giving more than one
drug (combination chemotherapy) may kill more tumor cells.

PRIMARY OBJECTIVES:

I. To determine the maximum tolerated dose and recommended phase II dose of ixabepilone when
combined with pegylated doxorubicin hydrochloride (HCl) liposome (pegylated liposomal
doxorubicin hydrochloride) in women with previously treated advanced ovarian epithelial,
primary peritoneal cavity, or fallopian tube cancer or metastatic breast cancer.

II. To determine the safety profile of this regimen in these patients. III. To determine the
clinical efficacy of this regimen in patients with platinum- and taxane-resistant advanced
ovarian epithelial, primary peritoneal cavity, or fallopian tube cancer.

OUTLINE: This is a phase I, multicenter, open-label, dose-escalation study of ixabepilone
followed by a phase II study.

Patients receive ixabepilone intravenously (IV) over 3 hours and pegylated liposomal
doxorubicin hydrochloride IV over 30-60 minutes on day 1. Courses repeat every 21-28 days in
the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed for up to 2 years.

Inclusion Criteria:

- Histologically or cytologically confirmed diagnosis of 1 of the following: advanced
ovarian epithelial, primary peritoneal cavity, or fallopian tube cancer (phase I and
II) or metastatic breast cancer (phase I only).

- Platinum- and taxane-resistant disease, defined as a disease-free interval of < 6
months after completion of platinum- and taxane-based chemotherapy. Disease
progression during the regimen (phase II) or previously treated with >= 2 prior
regimens for metastatic breast cancer, including 1 taxane-based regimen in the
adjuvant or metastatic setting (phase I).

- Meets 1 of the following criteria: Previously treated with a standard course of
taxane- and platinum-based chemotherapy for ovarian epithelial, primary peritoneal
cavity, or fallopian tube cancer, that is platinum-refractory or -sensitive disease
(phase I );

- Measurable or evaluable disease, meeting 1 of the following criteria:
unidimensionally measurable lesion, known disease and CA 125 > 50 U/mL on 2 occasions
>= 1 week apart or known disease and CA 27-29, CA 15-3, or CA 125 > 50 U/mL on 2
occasions >= 1 week apart (for breast cancer patients)

- ECOG 0-2 or Karnofsky 60-100%

- At least 3 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin) and
recovered.

- At least 1 week since prior chemotherapy if given on a daily or weekly schedule and
recovered.

- At least 3 weeks since prior radiotherapy and recovered.

- Recovered for more than 4 weeks from all adverse events related to prior agents.

- Normal organ function including:

- Normal bilirubin

- WBC >= 3,000/mm3

- Absolute neutrophil count >= 1,500/mm3

- Platelet count >= 100,000/mm3

- AST and ALT =< 2.5 times upper limit of normal (ULN)

- Creatinine =< 1.5 times ULN or Creatinine clearance ≥ 60 mL/min

Exclusion criteria:

- No other concurrent investigational agents.

- No concurrent combination antiretroviral therapy for HIV-positive patients.

- No other concurrent anticancer therapy.

- Has received a previous chemotherapy regimen for this cancer that included drugs such
as docetaxel or paclitaxel.

- Life expectancy of more than 3 months

- No symptomatic congestive heart failure

- No unstable angina pectoris

- No cardiac arrhythmia

- Not pregnant or nursing

- Fertile patients must use effective contraception

- No history of allergic reaction attributed to compounds of similar chemical or
biological composition to Cremophor® or study drugs

- No neuropathy >= grade 2

- No ongoing or active infection

- No psychiatric illness or social situation that would preclude study compliance.

- No other uncontrolled illness.

- No active brain metastases, including any of the following: evidence of cerebral
edema by CT scan or MRI, evidence of disease progression on prior imaging studies,
requirement for steroids or clinical symptoms of brain metastasis.
We found this trial at
5
sites
Albany, New York 12208
?
mi
from
Albany, NY
Click here to add this to my saved trials
1300 Morris Park Ave
Bronx, New York 10461
(718) 430-2000
Albert Einstein College of Medicine The Albert Einstein College of Medicine of Yeshiva University is...
?
mi
from
Bronx, NY
Click here to add this to my saved trials
?
mi
from
Bronx, NY
Click here to add this to my saved trials
Farmington, Connecticut 06030
?
mi
from
Farmington, CT
Click here to add this to my saved trials
445 E 69th St
New York, New York 10021
(212) 746-1067
Weill Medical College of Cornell University Founded in 1898, and affiliated with what is now...
?
mi
from
New York, NY
Click here to add this to my saved trials